Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
Darolutamide is developed jointly by Bayer and Orion Corporation
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Funding to grow the insurance and digital therapeutics vertical in India
Parkinson's disease treatment is the first and only carbidopa/levodopa (CD/LD) tablet designed to be divided for precise dosing
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied. Vaccine was well-tolerated with no safety signals identified
Subscribe To Our Newsletter & Stay Updated
